Oxford Immunotec Ranked Among Deloitte's 2015 Technology Fast 500(TM)

Attributes ~300 Percent Revenue Growth to Commercial Uptake of Proprietary T-SPOT® Technology

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (NASDAQ:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it has been included in Deloitte's 2015 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Oxford Immunotec was ranked 251^st in the list of 500, based upon Deloitte's assessment that the Company grew annual revenue 292 percent during this period.

"The Company is honored to be included among such prestigious technology companies.  This recognition is a direct reflection of the diligent efforts of all the members of the Oxford Immunotec team," said Peter Wrighton-Smith Ph.D., Chief Executive Officer of Oxford Immunotec. "Our growth in recent years can be attributed to the successful global commercialization of our T-SPOT platform, which allows for the examination of immune responses on a single cell level.  Our T-SPOT.TB test has improved the diagnosis of tuberculosis infection around the world and we continue to leverage our technology in the development of innovative diagnostic tests for other immune-regulated conditions including chronic infections, transplantation, autoimmune and inflammatory disease and immune-oncology."

"Amid a fierce business climate, there appears to be no shortage of new and established companies that are unlocking growth and advancement through the continued disruption and proliferation of innovation," said Sandra Shirai, principal, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. "It is inspiring to witness the dynamic ways that companies are incorporating emerging technologies for business gains in medical device, pharmaceuticals or diagnostic testing. We congratulate all those ranked on this year's Fast 500 and look forward to seeing their continued growth into 2016."